Header image

Theme B Proffered Paper Session 3: Treatment

Tracks
.
Monday, September 24, 2018
4:00 PM - 5:35 PM
Grand Lodge (Level 1)

Speaker

Agenda Item Image
Prof Andrew Carr
Director - HIV and Immunology Unit
St Vincent's Hospital, Sydney

Success And Failure Of Initial Antiretroviral Therapy (Art) In Adults: An Updated Systematic Review Including 77,999 Subjects From 1994 To 2017

4:00 PM - 4:15 PM

Abstract

Speaker Presentation

Biography

Professor Andrew Carr is a clinical immunologist and immunopathologist, and Head of the HIV, Immunology and Infectious Diseases Unit and of the Clinical Research Program, Centre for Applied Medical Research, St Vincent’s Hospital, Sydney. He has authored more than 300 peer-reviewed publications, mostly on antiretroviral complications and comorbidities.
Agenda Item Image
Dr Jillian Lau
Infectious Diseases Physician
Doherty Institute

Antiretroviral Treatment Interruptions In HIV Clinical Trials: A Systematic Review

4:15 PM - 4:30 PM

Abstract

Audio Recording

Speaker Presentation

Biography

Jillian Lau is an Infectious Diseases Physician who has an interest in HIV cure research, in particular antiretroviral treatment interruptions in HIV cure clinical trials. She is completing a PhD exploring social and clinicial research into HIV cure.
Agenda Item Image
Dr David Baker
Director
East Sydney Doctors

Durable Suppression 2 Years After Switch To Dolutegravir + Rilpivirine 2-Drug Regimen: Sword 1&2 Studies

4:30 PM - 4:45 PM

Abstract

Audio Recording

Speaker Presentation

Biography

Dr David Baker has worked for over 20 years in a high HIV case load General Practice, he's a senior lecturer at the University of Notre Dame and a clinical advisor to ASHM. He has a special interest in the care of people who inject drugs and in HIV-HCV co-infection.
Prof Don Smith
Senior staff Specialist
The Albion Centre

Switch To Bictegravir/F/TAF From DTG And ABC/3TC

4:45 PM - 5:00 PM

Abstract

Audio Recording

Speaker Presentation

Biography

Don Smith's research interests include the impact of antiretroviral therapy at different stages of disease is of interest. International collaborations have concentrated on the effects of therapy during primary HIV infection on immunological and virological outcomes.
Agenda Item Image
Dr David Baker
Director
East Sydney Doctors

Phase 3 Randomised, Controlled Trial Of Switching To Fixed-Dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Boosted Protease Inhibitor-Based Regimens In Virologically Suppressed Adults: Week 48 Results

5:00 PM - 5:15 PM

Abstract

Audio Recording

Speaker Presentation

Biography

David Baker has worked in Darlinghurst for over twenty years. He has a special interest in Sexual Health and HIV Medicine as well as Addiction Medicine and Hepatitis C. David has completed additional training at University of Sydney – the Diploma in Medicine (Sexual Health).
Rainer Puhr
Statistician
The Kirby Institute

Twenty Years Of Effective Antiretroviral Therapy: Investigating Response To Treatment And Changes In Treatment In Australia

5:15 PM - 5:30 PM

Abstract

Biography

Rainer is a statistician at the Kirby Institute, UNSW Sydney.
Dr Timothy Barnes
General Practitioner
Holdsworth House Medical Practice

High HBV And HIV Suppression With Treatment Of HIV/HBV Coinfection In B/F/TAF Studies

5:30 PM - 5:35 PM

Abstract

Audio Recording

Speaker Presentation

Biography

Dr Tim Barnes joins Holdsworth House having spent the previous eight years consulting in HIV medicine at The Albion Centre. Prior to this he worked for many years in general practice in Sydney following residency at Sydney Hospital.

Chair

Craig Cooper
Executive DIrector
Northern Territory AIDS & Hepatitis C Council

Agenda Item Image
Kate Mackie
Senior Clinical Pharmacist
Alfred Health

loading